Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17


Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration.

Wang G, Durussel J, Shurlock J, Mooses M, Fuku N, Bruinvels G, Pedlar C, Burden R, Murray A, Yee B, Keenan A, McClure JD, Sottas PE, Pitsiladis YP.

BMC Genomics. 2017 Nov 14;18(Suppl 8):817. doi: 10.1186/s12864-017-4191-7.


Autologous Doping with Cryopreserved Red Blood Cells - Effects on Physical Performance and Detection by Multivariate Statistics.

Malm CB, Khoo NS, Granlund I, Lindstedt E, Hult A.

PLoS One. 2016 Jun 10;11(6):e0156157. doi: 10.1371/journal.pone.0156157. eCollection 2016.


The influence of artificially introduced N-glycosylation sites on the in vitro activity of Xenopus laevis erythropoietin.

Nagasawa K, Meguro M, Sato K, Tanizaki Y, Nogawa-Kosaka N, Kato T.

PLoS One. 2015 Apr 21;10(4):e0124676. doi: 10.1371/journal.pone.0124676. eCollection 2015.


Serum proteomic changes after randomized prolonged erythropoietin treatment and/or endurance training: detection of novel biomarkers.

Christensen B, Ludvigsen M, Nellemann B, Kopchick JJ, Honoré B, Jørgensen JO.

PLoS One. 2015 Feb 13;10(2):e0117119. doi: 10.1371/journal.pone.0117119. eCollection 2015.


Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin.

Jiang J, Tian F, Cai Y, Qian X, Costello CE, Ying W.

Anal Bioanal Chem. 2014 Oct;406(25):6265-74. doi: 10.1007/s00216-014-8037-8. Epub 2014 Jul 31.


Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S.

Endocr Rev. 2014 Jun;35(3):341-75. doi: 10.1210/er.2013-1058. Epub 2013 Dec 17. Review.


Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer's disease.

Arabpoor Z, Hamidi G, Rashidi B, Shabrang M, Alaei H, Sharifi MR, Salami M, Dolatabadi HR, Reisi P.

Adv Biomed Res. 2012;1:50. doi: 10.4103/2277-9175.100157. Epub 2012 Aug 28.


Erythropoietin prevents PC12 cells from beta-amyloid-induced apoptosis via PI3K⁄Akt pathway.

Zhi-Kun S, Hong-Qi Y, Zhi-Quan W, Jing P, Zhen H, Sheng-Di C.

Transl Neurodegener. 2012 Feb 29;1(1):7. doi: 10.1186/2047-9158-1-7.


Erythropoietin use and abuse.

John MJ, Jaison V, Jain K, Kakkar N, Jacob JJ.

Indian J Endocrinol Metab. 2012 Mar;16(2):220-7. doi: 10.4103/2230-8210.93739.


Organ specific regenerative markers in peri-organ adipose: kidney.

Basu J, Genheimer CW, Sangha N, Quinlan SF, Guthrie KI, Kelley R, Ilagan RM, Jain D, Bertram T, Ludlow JW.

Lipids Health Dis. 2011 Sep 29;10:171. doi: 10.1186/1476-511X-10-171.


Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control.

Lasne F, Martin L, Martin JA, de Ceaurriz J.

Haematologica. 2009 Jun;94(6):888-90. doi: 10.3324/haematol.2009.006809. No abstract available.


Illicit organogenesis: Methods and substances of doping and manipulation.

Thevis M, Schänzer W.

Organogenesis. 2008 Oct;4(4):264-71.


Caspase activation, sialidase release and changes in sialylation pattern of recombinant human erythropoietin produced by CHO cells in batch and fed-batch cultures.

Chuan KH, Lim SF, Martin L, Yun CY, Loh SO, Lasne F, Song Z.

Cytotechnology. 2006 Jun;51(2):67-79. doi: 10.1007/s10616-006-9016-5. Epub 2006 Sep 20.


Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.

Elliott S.

Br J Pharmacol. 2008 Jun;154(3):529-41. doi: 10.1038/bjp.2008.89. Epub 2008 Mar 24. Review.


Variability in the immunodetection of His-tagged recombinant proteins.

Debeljak N, Feldman L, Davis KL, Komel R, Sytkowski AJ.

Anal Biochem. 2006 Dec 15;359(2):216-23. Epub 2006 Nov 1.


Erythropoietin and blood doping.

Robinson N, Giraud S, Saudan C, Baume N, Avois L, Mangin P, Saugy M.

Br J Sports Med. 2006 Jul;40 Suppl 1:i30-4.

Supplemental Content

Support Center